EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy
(2022) In European Urology Oncology 5(5). p.530-536- Abstract
BACKGROUND: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is useful for selected clinical indications in patients with prostate cancer (PCa) but it may have broader clinical utility owing to the emergence of lutetium-177-PSMA-617 ([177Lu]Lu-PSMA) therapy. However, robust data regarding the impact of PSMA PET/CT on patient management and treatment are lacking, and in many areas, the role of next-generation imaging has not been defined. OBJECTIVE: To assess expert opinion on the use of PSMA-based imaging and therapy to develop interim guidance. DESIGN, SETTING, AND PARTICIPANTS: A panel of 21 PCa experts from various disciplines received thematic topics and relevant literature. A... (More)
BACKGROUND: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is useful for selected clinical indications in patients with prostate cancer (PCa) but it may have broader clinical utility owing to the emergence of lutetium-177-PSMA-617 ([177Lu]Lu-PSMA) therapy. However, robust data regarding the impact of PSMA PET/CT on patient management and treatment are lacking, and in many areas, the role of next-generation imaging has not been defined. OBJECTIVE: To assess expert opinion on the use of PSMA-based imaging and therapy to develop interim guidance. DESIGN, SETTING, AND PARTICIPANTS: A panel of 21 PCa experts from various disciplines received thematic topics and relevant literature. A questionnaire to assess proposed guidance statements regarding PSMA PET/CT and [177Lu]Lu-PSMA therapy was developed for completion remotely in a first e-Delphi round. A subsequent panel discussion was conducted during a 1-d meeting, which included a second Delphi round. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Panellists voted anonymously on statements using a nine-point Likert scale from 1 = strongly disagree to 9 = strongly agree. Median scores were calculated and consensus was assessed using methods proposed by the Research and Development (RAND) corporation. RESULTS AND LIMITATIONS: Statements were developed to cover the following topics: PSMA PET/CT utility, clinical use, and choice of tracer; patient selection; and management of patients receiving [177Lu]Lu-PSMA for metastatic PCa. Consensus was reached for 33/36 statements. In-group bias is a potential limitation, as some statements were rephrased during discussions at the 1-d meeting. CONCLUSIONS: Adoption of PSMA PET/CT as an imaging tool to guide [177Lu]Lu-PSMA therapy should be supported by indications for appropriate use. PATIENT SUMMARY: A panel of experts in prostate cancer reached a consensus for the majority of statements proposed regarding the role of prostate-specific membrane antigen (PSMA)-based imaging and therapy, particularly the use of PSMA-based imaging in patients suitable for [177Lu]Lu-PSMA therapy and the need to perform PSMA-based imaging before considering patients as candidates for this therapy.
(Less)
- author
- organization
- publishing date
- 2022-10-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Computed tomography, Consensus, Diagnosis, Lutetium, Patient selection, Positron emission tomography, Prostate cancer, Prostate-specific membrane antigen, Radioactive tracer, Therapy
- in
- European Urology Oncology
- volume
- 5
- issue
- 5
- pages
- 7 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:35697600
- scopus:85139488755
- ISSN
- 2588-9311
- DOI
- 10.1016/j.euo.2022.05.003
- language
- English
- LU publication?
- yes
- id
- a4db4ef8-263e-401f-900b-eb7da256808c
- date added to LUP
- 2022-12-09 14:29:41
- date last changed
- 2024-05-16 10:02:12
@article{a4db4ef8-263e-401f-900b-eb7da256808c,
abstract = {{<p>BACKGROUND: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is useful for selected clinical indications in patients with prostate cancer (PCa) but it may have broader clinical utility owing to the emergence of lutetium-177-PSMA-617 ([177Lu]Lu-PSMA) therapy. However, robust data regarding the impact of PSMA PET/CT on patient management and treatment are lacking, and in many areas, the role of next-generation imaging has not been defined. OBJECTIVE: To assess expert opinion on the use of PSMA-based imaging and therapy to develop interim guidance. DESIGN, SETTING, AND PARTICIPANTS: A panel of 21 PCa experts from various disciplines received thematic topics and relevant literature. A questionnaire to assess proposed guidance statements regarding PSMA PET/CT and [177Lu]Lu-PSMA therapy was developed for completion remotely in a first e-Delphi round. A subsequent panel discussion was conducted during a 1-d meeting, which included a second Delphi round. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Panellists voted anonymously on statements using a nine-point Likert scale from 1 = strongly disagree to 9 = strongly agree. Median scores were calculated and consensus was assessed using methods proposed by the Research and Development (RAND) corporation. RESULTS AND LIMITATIONS: Statements were developed to cover the following topics: PSMA PET/CT utility, clinical use, and choice of tracer; patient selection; and management of patients receiving [177Lu]Lu-PSMA for metastatic PCa. Consensus was reached for 33/36 statements. In-group bias is a potential limitation, as some statements were rephrased during discussions at the 1-d meeting. CONCLUSIONS: Adoption of PSMA PET/CT as an imaging tool to guide [177Lu]Lu-PSMA therapy should be supported by indications for appropriate use. PATIENT SUMMARY: A panel of experts in prostate cancer reached a consensus for the majority of statements proposed regarding the role of prostate-specific membrane antigen (PSMA)-based imaging and therapy, particularly the use of PSMA-based imaging in patients suitable for [177Lu]Lu-PSMA therapy and the need to perform PSMA-based imaging before considering patients as candidates for this therapy.</p>}},
author = {{Fanti, Stefano and Briganti, Alberto and Emmett, Louise and Fizazi, Karim and Gillessen, Silke and Goffin, Karolien and Hadaschik, Boris A. and Herrmann, Ken and Kunikowska, Jolanta and Maurer, Tobias and MacLennan, Steven and Mottet, Nicolas and Murphy, Declan G. and Oprea-Lager, Daniela E. and O'Sullivan, Joe M. and Oyen, Wim J.G. and Rouvière, Olivier and Sartor, Oliver and Stenzl, Arnulf and Van Poppel, Hendrik and Walz, Jochen and Witjes, Wim and Bjartell, Anders}},
issn = {{2588-9311}},
keywords = {{Computed tomography; Consensus; Diagnosis; Lutetium; Patient selection; Positron emission tomography; Prostate cancer; Prostate-specific membrane antigen; Radioactive tracer; Therapy}},
language = {{eng}},
month = {{10}},
number = {{5}},
pages = {{530--536}},
publisher = {{Elsevier}},
series = {{European Urology Oncology}},
title = {{EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [<sup>177</sup>Lu]Lu-PSMA Radioligand Therapy}},
url = {{http://dx.doi.org/10.1016/j.euo.2022.05.003}},
doi = {{10.1016/j.euo.2022.05.003}},
volume = {{5}},
year = {{2022}},
}